Search Results - Matthijs Westerman
- Showing 1 - 6 results of 6
-
1
-
2
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CAS... by Cyrille Hulin, Fritz Offner, Philippe Moreau, Murielle Roussel, Karim Belhadj, Lotfi Benboubker, Denis Caillot, Thierry Facon, Laurent Garderet, Frédérique Kuhnowski, Anne-Marie Stoppa, Brigitte Kolb, Mourad Tiab, Kon-Siong Jie, Matthijs Westerman, Jérôme Lambert, Lixia Pei, Veronique Vanquickelberghe, Carla de Boer, Jessica Vermeulen, Tobias Kampfenkel, Pieter Sonneveld, Niels W.C.J. van de Donk
Published in Haematologica (2021-03-01)Get full text
Article -
3
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes by Kazimierz Groen, Febe Smits, Kazem Nasserinejad, Mark‐David Levin, Josien C. Regelink, Gert‐Jan Timmers, Esther G. M. deWaal, Matthijs Westerman, Gerjo A. Velders, Koen deHeer, Rineke B. L. Leys, Roel J. W. vanKampen, Claudia A. M. Stege, Maarten R. Seefat, Inger S. Nijhof, Ellen van derSpek, Saskia K. Klein, Niels W. C. J. van deDonk, Paula F. Ypma, Sonja Zweegman
Published in HemaSphere (2024-07-01)Get full text
Article -
4
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a... by Lene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, Bronno van der Holt, Ulf-Henrik Mellqvist, Morten Salomo, Gerard Bos, Mark-David Levin, Heleen Visser-Wisselaar, Markus Hansson, Annette van der Velden, Wendy Deenik, Juleon Coenen, Maja Hinge, Saskia Klein, Bea Tanis, Damian Szatkowski, Rolf Brouwer, Matthijs Westerman, Rineke Leys, Harm Sinnige, Einar Haukås, Klaas van der Hem, Marc Durian, Peter Gimsing, Niels van de Donk, Pieter Sonneveld, Anders Waage, Niels Abildgaard, Sonja Zweegman
Published in Haematologica (2020-06-01)Get full text
Article -
5
P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE... by Kaz Groen, Claudia Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. van Kampen, Rineke B.L. Leys, Noortje Thielen, Matthijs Westerman, Ka-Lung Wu, Inge Ludwig, Djamila E. Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Niels W.C.J. van de Donk, Gert-Jan Timmers, Fransien de Boer, Lidwine W. Tick, Ellen van der Spek, Esther G.M. de Waal, Maaike Sohne, Pieter Sonneveld, Inger S. Nijhof, Saskia K. Klein, Mark-David Levin, Paula F. Ypma, Sonja Zweegman
Published in HemaSphere (2023-08-01)Get full text
Article -
6
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context by Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. van Kampen, Rineke B.L. Leys, Noortje Thielen, Matthijs Westerman, Ka-Lung Wu, Inge Ludwig, Djamila E. Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Gert-Jan Timmers, Fransien de Boer, Lidwine W. Tick, Annelies Verbrugge, Danny Buitenhuis, Sonia M. Cunha, Ellen van der Spek, Esther G.M. de Waal, Maaike Sohne, Pieter Sonneveld, Inger S. Nijhof, Saskia K. Klein, Niels W.C.J. van de Donk, Mark-David Levin, Paula F. Ypma, Sonja Zweegman
Published in EClinicalMedicine (2023-09-01)Get full text
Article
